© The Financial Times Ltd 2013 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Dec 04, 2013, the consensus forecast amongst 37 polled investment analysts covering AstraZeneca plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 31, 2009. The previous consensus forecast advised that AstraZeneca plc would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for
|Div growth (TTM)||0.00%|
On Oct 31, 2013,
The next earnings announcement is expected on Feb 06, 2014. View Full Interim Financials
|Average growth rate||-4.88%|
The next earnings announcement from
|Average growth rate||+8.34%|
AstraZeneca PLC had 3rd quarter 2013 revenues of 6.2500bn. This missed the 6.4438bn consensus estimate of the 12 analysts following the company. This was 0.29% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||-1.36%|
AstraZeneca PLC had revenues for the full year 2012 of 27.9730bn. This was 16.72% below the prior year's results. View Full Annual Financials
|Average growth rate||-2.63%|